MedinGlobal

Edit Template

Evermil 5 mg

In Stock

Evermil 5 mg contains Everolimus 5 mg, an anticancer medicine belonging to the mTOR inhibitor category. It is associated with selected advanced cancers, including specific kidney, breast and neuroendocrine tumours. The medicine blocks mTOR signalling that supports abnormal cell growth and division. Suitability depends on the diagnosis, approved labeling, clinical history and specialist assessment. The 5 mg oncology presentation must not be confused with transplant formulations. A qualified clinician should confirm whether this exact brand, strength and formulation are appropriate before any prescription or treatment decision.

Medinglobal provides product information and medicine enquiry coordination. Availability and any subsequent supply are subject to confirmation by an authorised independent provider and applicable regulations.

Evermil 5 mg – Composition, Uses and Medicine Enquiries

Product Overview

Evermil 5 mg is a product listed under the anticancer category and is classified as an mTOR inhibitor.

Its active composition is Everolimus 5 mg.

It is associated with selected advanced cancers, including specific kidney, breast and neuroendocrine tumours.

The medicine blocks mTOR signalling that supports abnormal cell growth and division.

Suitability depends on the diagnosis, approved labeling, clinical history and specialist assessment.

This information is provided for education and product identification, not as a recommendation to begin treatment.

The master sheet calls this a transplant drug; however, the 5 mg oncology presentation must not be confused with transplant formulations.

A qualified clinician should confirm whether this exact brand, strength and formulation are appropriate before any prescription or treatment decision.

Composition and Strength

The supplied product information identifies the following composition:

Active Ingredient Strength
Everolimus 5 mg

Product Name: Evermil 5 mg

Generic Name: Everolimus

Brand Name: Evermil

Strength: 5 mg

Please verify the exact strength, dosage form, product labeling and manufacturer details against the original product packaging before publishing this product page or proceeding with an enquiry.

The 5 mg oncology presentation must not be conflated with transplant formulations.

Therapeutic Category and Indication

Evermil 5 mg belongs to the anticancer medicine category and is classified as an mTOR inhibitor.

Its principal clinical use is associated with selected advanced cancers, including specific kidney, breast and neuroendocrine tumours.

The active ingredient blocks mTOR signalling that supports abnormal cell growth and division.

Treatment eligibility may depend on diagnostic tests, organ function, other medicines and the relevant national prescribing information.

The original spreadsheet category or indication may not accurately represent the brand-specific approval. A qualified pharmacist should check the approved product label before publication.

The master sheet calls this a transplant drug; the 5 mg oncology presentation must not be confused with transplant formulations.

Administration Information

Evermil 5 mg is supplied as an oral tablet according to the provided product information.

The tablet should be taken consistently with or without food as prescribed by the oncology team.

Patients should follow the exact prescribed route, dose and schedule.

Do not change, share or discontinue this medicine without the treating professional’s advice.

Patients should also review the manufacturer’s patient instructions.

Product Presentation and Availability

The product enquiry can be made using the following details:

  • Product Name: Evermil 5 mg
  • Generic Name: Everolimus
  • Brand Name: Evermil
  • Strength: 5 mg
  • Therapeutic Category: Anticancer
  • Medicine Class: mTOR Inhibitor
  • Indication: Selected advanced cancers, including specific kidney, breast and neuroendocrine tumours.
  • Dosage Form: Oral Tablets.
  • Route of Administration: Oral.

The master spreadsheet lists Glenmark as manufacturer/marketer. This attribution and the current pack size, dosage form, labeling, batch details and expiry must be independently verified.

No particular packaging, stock or delivery is promised by Medinglobal.

Prescription and Patient Safety

Evermil 5 mg is a prescription anticancer medicine requiring appropriate specialist supervision.

Treatment suitability depends on the diagnosis, approved labeling, clinical history and specialist assessment.

The 5 mg oncology presentation must not be confused with transplant formulations.

Patients should follow the oncology team’s instructions and should not independently change, share or discontinue the medicine.

The exact precautions, monitoring requirements and possible adverse effects should be checked against the current approved product information.

Medicine Enquiry Coordination Through Medinglobal

Medinglobal receives enquiries about Evermil 5 mg and may coordinate requests for product information with independent, appropriately authorised pharmaceutical providers.

Medinglobal is not the manufacturer, direct seller, dispensing pharmacy or exporter of this product.

Any permitted transaction, prescription check, destination-country assessment, supply terms and supporting documentation are handled by the relevant authorised provider.

An enquiry does not guarantee availability or supply.

How to Submit an Evermil 5 mg Enquiry

To help identify the requested product, include the following details when submitting an enquiry:

  1. Product or brand name: Evermil 5 mg.
  2. Generic name: Everolimus.
  3. Required strength and formulation.
  4. Required quantity.
  5. Destination country.
  6. Valid prescription or institutional documents, when required.

Medinglobal may connect the enquiry with an appropriately authorised independent provider, which must independently confirm legality, product identity and any applicable commercial terms.

Frequently Asked Questions

What is Evermil 5 mg used for?

It is associated with selected advanced cancers, including specific kidney, breast and neuroendocrine tumours, subject to the exact approved label and medical assessment.

What does Evermil 5 mg contain?

It contains Everolimus 5 mg. The final composition should be confirmed against the manufacturer’s product packaging.

How is Evermil 5 mg administered?

It is taken orally as a tablet, consistently with or without food as prescribed by the oncology team.

Is Evermil 5 mg an oncology or transplant medicine?

The supplied product information identifies Evermil 5 mg as an anticancer medicine and an mTOR inhibitor. Its 5 mg oncology presentation must not be confused with transplant formulations.

Can I request product information through Medinglobal?

Yes. Medinglobal can coordinate product information enquiries, but supply is neither guaranteed nor directly undertaken by Medinglobal.

Product Name

Generic Name

Brand Name

Composition

Strength

Therapeutic Category

Medicine Class

Indication

Dosage Form

Route of Administration

Reviews

There are no reviews yet.

Be the first to review “Evermil 5 mg”

Your email address will not be published. Required fields are marked *

Pharmaceutical Disclaimer

Medinglobal Platform does not sell, dispense, manufacture or prescribe medicines. Pharmaceutical information on this page is provided solely for general information, product identification and enquiry coordination. Product listing is not medical advice, a recommendation or an offer for sale by Teji Radiance or the Medinglobal Partnership Firm. Prescription medicines require a valid prescription where applicable. Any regulated pharmaceutical activity is undertaken by the relevant independent provider subject to applicable law. Always consult an appropriately qualified healthcare professional before using or changing any medicine.

Scroll to Top